Consensus Clene Inc.

Stocks

CLNN

US1856342019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 28/07/2026 +04			5-day change	1st Jan Change
5.460 ^USD	+1.30%		-4.71%	-6.98%

06-29	Clene Inc.(NasdaqCM:CLNN) added to Russell Microcap Value Benchmark Index	CI
06-29	Clene Inc.(NasdaqCM:CLNN) added to Russell Microcap Index	CI

Evolution of the Average Target: Clene Inc.

Evolution of the Target Price: Clene Inc.

Changes in Analyst Recommendations: Clene Inc.

3f0c3.xFZs_dq9xTwSV9lo9PNZWPRjLP2ZPukEyrwuJEKypII.khpbjOLKk3FRDZgdnL4PFJJUSMjhetBpn81EZnbh1cWTLhui7--qdmVhtg~6029f377da2d41399b9e6d0d773a25bc

Analysts' recommendations: Clene Inc.

10/09/24	EF Hutton Initiates Clene at Buy With $23 Price Target	MT
30/06/23	Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	MT
21/06/23	HC Wainwright Cuts Price Target on Clene to $7 From $15, Keeps Buy Rating	MT
20/06/23	EF Hutton Adjusts Clene Price Target to $10 From $13, Maintains Buy Rating	MT
16/05/23	Cantor Fitzgerald Adjusts Price Target on Clene to $4 From $5, Maintains Overweight Rating	MT
10/04/23	Benchmark Adjusts Price Target on Clene to $7 From $11, Keeps Buy Rating	MT
10/03/23	Cantor Fitzgerald Adjusts Price Target on Clene to $8 From $6, Maintains Buy Rating	MT
08/03/23	EF Hutton Starts Clene at Buy With $13 Price Target	MT
04/10/22	Oppenheimer Downgrades Clene to Perform From Outperform, Removes $17 Price Target	MT
04/10/22	Benchmark Adjusts Clene's Price Target to $11 From $25, Reiterates Buy Rating	MT
04/10/22	Canaccord Genuity Adjusts Clene's Price Target to $6 From $10, Reiterates Buy Rating	MT
17/08/22	Oppenheimer Adjusts Clene's Price Target to $17 From $16, Maintains Outperform Rating	MT
16/08/22	Cantor Fitzgerald Adjusts Clene Price Target to $12 From $10, Maintains Overweight Rating	MT
18/07/22	HC Wainwright Initiates Clene at Buy With $16 Price Target	MT
02/05/22	Canaccord Genuity Starts Clene at Buy With $10 Price Target	MT
15/02/22	Oppenheimer Adjusts Clene's Price Target to $19 From $20, Maintains Outperform Rating	MT
03/11/21	Cantor Fitzgerald Adjusts Clene's Price Target to $15 From $24, Reiterates Overweight Rating	MT
28/09/21	CLENE : Oppenheimer Initiates Coverage on Clene With Outperform Rating, $20 Price Target	MT
20/05/21	CLENE : Maxim Group Starts Clene at Buy With $18 Price Target	MT
03/05/21	CLENE : Cantor Fitzgerald Starts Clene at Overweight With $22 Price Target	MT
02/03/21	CLENE : Benchmark Starts Clene at Buy With $25 Price Target	MT
03/02/21	CLENE : Roth Capital Starts Clene at Buy with $24 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CLENE INC.					+497.4%
	ARGENX SE					+12.4%
	WUXI APPTEC CO., LTD.					+20.38%
	INSMED INCORPORATED					+83.48%
	BIONTECH SE					+36.04%
	WUXI BIOLOGICS (CAYMAN) INC.					+20.54%
	GENMAB A/S					+27.34%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+10.33%
	PHARMAESSENTIA CORPORATION					-5.44%
	EXELIXIS, INC.					-5.97%
	Average					+69.65%
	Weighted average by Cap.					+22.82%